Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Johan Bodegård

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10

Diabetes Care

English

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014

PharmacoEconomics - Open

Health Policy

Pharmacology

2017

English

Related publications

Comment on Andersen Et Al. Risk-Factor Trajectories Preceding Diabetic Polyneuropathy: ADDITION-Denmark. Diabetes Care 2018;41:1955–1962

English

Response to Comment on Lacy Et Al. Long-Term Glycemic Control and Dementia Risk in Type 1 Diabetes. Diabetes Care 2018;41:2339–2345

English

Comment on Warren Et Al. Diabetes and Trajectories of Estimated Glomerular Filtration Rate: A Prospective Cohort Analysis of the Atherosclerosis Risk in Communities Study. Diabetes Care 2018;41:1646–1653

English

SGLT2 Inhibitors

2020

English

SGLT2 Inhibitors: Alternatives or Complementary Therapeutic Options

2020

English

Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579–1589

English

Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579–1589

English

Comment on Bril Et Al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187–192

English

Comment on Itoh Et Al. Intensive Treat-To-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018;41:1275–1284

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Johan Bodegård

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014

Related publications

Comment on Andersen Et Al. Risk-Factor Trajectories Preceding Diabetic Polyneuropathy: ADDITION-Denmark. Diabetes Care 2018;41:1955–1962

Response to Comment on Lacy Et Al. Long-Term Glycemic Control and Dementia Risk in Type 1 Diabetes. Diabetes Care 2018;41:2339–2345

Comment on Warren Et Al. Diabetes and Trajectories of Estimated Glomerular Filtration Rate: A Prospective Cohort Analysis of the Atherosclerosis Risk in Communities Study. Diabetes Care 2018;41:1646–1653

SGLT2 Inhibitors

SGLT2 Inhibitors: Alternatives or Complementary Therapeutic Options

Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579–1589

Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579–1589

Comment on Bril Et Al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187–192

Comment on Itoh Et Al. Intensive Treat-To-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018;41:1275–1284